University Hospital Freiburg, Epilepsy Center, Breisacher Str. 64, D-79106 Freiburg, Germany.
Expert Opin Pharmacother. 2010 Jan;11(1):115-26. doi: 10.1517/14656560903468728.
More than 1 million epilepsy patients suffer from insufficiently controlled epilepsy, both in the USA and in Europe. Zonisamide is an antiepileptic drug with multiple mechanisms of action, corresponding to efficacy in diverse epilepsy syndromes.
Here, an update on pharmacodynamics, pharmacokinetics, clinical efficacy and safety in childhood and adult epilepsies is given based on an analysis of controlled and uncontrolled studies, European, US and East Asian, and on clinical experience with zonisamide (ZNS) published up to 2009.
Evidence is presented that ZNS is effective not only in adult focal epilepsies, for which it has been approved in the USA and in Europe, but also may offer treatment options for compassionate use in a spectrum of difficult-to-treat epilepsy syndromes. Its favorable pharmacokinetic profile allows for easy combination with most available antiepileptic drugs.
Provided that additional studies on ZNS are performed to extend approval and to generate comparative data, ZNS has a potential to gain importance in the treatmnt of a wide spectrum of epilepsy patients.
在美国和欧洲，有超过 100 万的癫痫患者患有控制不佳的癫痫。佐尼沙胺是一种具有多种作用机制的抗癫痫药物，对应于多种癫痫综合征的疗效。
在此，基于对对照和非对照研究、欧洲、美国和东亚的分析，以及截至 2009 年发表的关于佐尼沙胺（ZNS）的临床经验，对儿童和成人癫痫中的药效学、药代动力学、临床疗效和安全性进行了更新。
有证据表明，ZNS 不仅对已在美国和欧洲批准用于成人局灶性癫痫的药物有效，而且还可能为一系列难治性癫痫综合征提供同情用药的治疗选择。其有利的药代动力学特征允许与大多数现有的抗癫痫药物轻松联合使用。
只要对 ZNS 进行更多的研究来扩展批准范围并生成比较数据，那么 ZNS 就有可能在治疗广泛的癫痫患者方面变得更加重要。
